2024-11-01 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

This report provides a comprehensive analysis of Abbott Laboratories (ABT) stock based on the provided data and external resources.

**1.  Performance vs. S&P 500:**

* **Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, pharmaceuticals, and nutrition products.
* **Cumulative Return:** ABT's cumulative return is 102.98%, while the S&P 500 (VOO) has a cumulative return of 131.38%.
* **Performance Gap:**  ABT currently lags behind the S&P 500 by -28.4%. This represents a 13.96% relative underperformance, meaning it is positioned in the 13.96th percentile of its historical performance range compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $113.37
* **5-day Moving Average:** $113.90
* **20-day Moving Average:** $115.64
* **60-day Moving Average:** $114.00

**3. Technical Indicators:**

* **RSI:** 41.17 (Neutral) -  The RSI is currently in neutral territory, suggesting neither strong overbought nor oversold conditions.
* **PPO:** -0.42 (Weak Momentum) - The PPO indicates weak price momentum, with the price trailing its 20-day moving average.
* **Delta_Previous_Relative_Divergence:** 1.29 (+) (Short-term Upward Trend) - This indicates a short-term upward trend in price relative to the S&P 500.
* **Expected Return:** 0.0% -  The expected return is 0% over the long term (2 years or more) compared to the S&P 500, suggesting potential for modest gains.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue |
|------------|------|---------|
| 2024-10-31 | 0.94 | $10.63B |
| 2024-07-31 | 0.74 | $10.38B |
| 2024-05-02 | 0.70 | $9.96B |
| 2023-11-01 | 0.82 | $10.14B |
| 2024-10-31 | 0.82 | $10.14B |

* The latest earnings (2024-10-31) show EPS of 0.94, surpassing analyst expectations. This suggests a positive outlook for the company's future performance.

**5.  Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue  | Profit Margin |
|-------------|----------|--------------|
| 2024-06-30 | $10.38B | 55.64%      |
| 2024-03-31 | $9.96B  | 55.21%      |
| 2023-12-31 | $10.24B | 55.51%      |
| 2023-09-30 | $10.14B | 54.60%      |
| 2023-06-30 | $9.98B  | 55.07%      |

**Capital and Profitability:**

| Quarter     | Equity   | ROE   |
|-------------|----------|-------|
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |
| 2023-06-30 | $37.17B | 3.70% |

* Abbott has consistently maintained high profit margins and strong revenue growth, indicating a financially stable and profitable company.

**6.  News and Recent Issues:**

* **Recent Earnings News:** (Search for recent news articles on sources like Shacknews, etc.)
* **Market Outlook:**  (Check for recent market analysis and analyst opinions on platforms like FINBOLD)
* **Analyst Opinions and Performance Highlights:** (Refer to analysts' ratings and research reports for specific insights into the company's performance and future prospects)

**7.  Overall Analysis:**

Abbott Laboratories is a financially strong and consistent performer with a strong market position. The company shows stable earnings and revenue growth, supported by a robust balance sheet and high profit margins. While its recent performance has slightly lagged the S&P 500, its solid fundamentals and positive earnings suggest potential for future growth. 

The technical indicators are currently neutral to weakly positive, suggesting a potential for short-term upward movement, however, long-term investors may find the expected return to be relatively low.  The company's recent earnings beat expectations, supporting a positive outlook. 

Ultimately, the decision to invest in ABT should consider your personal investment strategy and risk tolerance. Conduct thorough research and consult with a financial advisor before making any investment decisions. 
